Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Drug metabolism and pharmacokinetics
ICT has an experienced Drug Metabolism and Pharmacokinetic (DMPK) Team, led by Prof Paul Loadman, who have worked on numerous contract research projects with industrial partners within efficient and well-resourced GCP laboratories. The team undertake analytical method development (LC-MS/MS) and a range of bioavailability and pharmacokinetic studies from simple evaluation of parent molecule in plasma to full ADME and tissue distribution.
Advantages of working with the DMPK team at ICT:
* Excellent knowledge and experience in this area- expert opinion from leading academics
* GCP accredited laboratories and high quality research and reporting
* Projects are managed to meet commercial timelines and we ensure our partners are fully updated on progress
* Examples of studies include the analysis of complex metabolic profiles and the development of analytical methods for the PK analysis of highly reactive and potent molecules in the picomolar range.
We have also successfully monitored low concentrations of highly potent metabolites and pharmacodynamic markers in small clinical biopsy samples as in a recent Phase I clinical trial.
Look who Avacta is flying out to AACR
P. Loadman,
Avacta Grant/Contract, Paid consultant.
https://www.abstractsonline.com/pp8/#!/20272/presentation/11478
Are they taking him to talk about the biopsy samples to BP.
Bella read the RNS below:
We have a patient still going from 3rd Cohort
The 59 year old with 65% reduction in tumour.
That’s massive that’s why I’m still in…….
28 Feb 2024 16:41
RNS Number : 8447E
The SDMC approved dose escalation to 120 mg/m2 in a second cohort, 160 mg/m2 in a third cohort, 200mg/m2 in a fourth cohort, 250mg/m2 in a fifth cohort, 310mg/m2 in a sixth cohort and 385mg/m2 in a seventh and final cohort.
A 59-year-old male with the diagnosis of undifferentiated pleomorphic sarcoma, treated at 160 mg/m2 on a three-weekly dosing ("Q3W"), resulted in a Partial Response with a duration of greater than 6 months and a tumour volume reduction of ~65%. Treatment is ongoing, with high FAP expression observed in the tumour tissue and a favourable PK profile with reduction in AUC which permits dosing for 7 additional cycles (~21 weeks)
BITL
Sp crashes after every interview excited Puppy interrupting waffle and not invested why ?
Preliminary Results and AGM are now just weeks away usually April with results in June.
Gardiner and Smith have weeks to save their jobs.
If SP isn’t back above £1:20 then Smith could be moved aside.
Put him back in the Lab and dont give him access to Zoom or Microsoft teams so he can’t contact that idiot at VOX and do more damage.
Even if SP gets above £2.00
I expect Gardiner to be gone, we need an experienced Pharma CFO to monopolise this platform.
This is a good read on guidance.
FDA defiantly engaged with Avacta.
https://www.fda.gov/media/166431/download
I wonder if Simon Bennett has finished his induction.
He could be with Gardiner helping him with his X tables.
This dated 7th December is this the patent mentioned in Q&A
Avacta has filed a patent for therapeutic conjugates with extended circulating serum half-life, linked through a FAPa-cleavable linker. The conjugates have a minimum 48-hour half-life in vivo and do not contain cell-binding moieties with a Kd of 1×10-6 M or less
https://www.pharmaceutical-technology.com/data-insights/avacta-group-files-patent-for-extended-circulating-serum-half-life-therapeutic-conjugates/
It’s not just about Smith & Forster the biggest problem is Gardiner he is the one holding the purse he should be sacked with his options cancelled .
If PI’s keep their incompetence in the news ahead of the science other BOD’s should start to look at a motion of no confidence against at least Gardiner.
CFO / Gardiner has got to go…
1/5 of working capital lost by not taking extra at over subscribed 95p and leaving fund raise to last minute,Naive at the highest level.
CEO / Smith at minimum move him sideways so he can’t do any more damage, promote CC.
Chair / Forster hold for now don’t need too many changes at the top but card marked.
If we can get CC in as CEO and an experienced CFO to replace Gardiner who hasn’t got a clue the SP could recover.
The FDA tweets this, let’s hope C7 results are smashing tumours and patients start to get wind of what is available.
“It doesn't take long for the FDA to grant an Expanded Access request. Review times are fast and a “granted” letter is usually sent within one day for both emergency and non-emergency requests. “
https://t.co/E0R4f0zisR
“or we’ll be back here again or lower in 2 years time!”
Back in a year if No LD or partnership,They will need 2 years cash to get signed off next year.
Bella
If you was on £400k a year you would drag it out.
If BP come knocking game over..
Bella read title
I said summer T/O
By then they will have AACR data and phase 2w data and if any leaks of a licence deal or a partnership game on….
We are all here now for a T/O the quicker the better for me,after last weeks shi te show by BOD.
If a major pharma wants the whole platform to improve their top line with expiring patents of their top selling drugs.
A low ball offer of £3bn which is criminally cheap, could start a bidding war.
They’ll need to start making moves soon before P2 starts.
If news starts to leak of a licence deal or a partnership it’s time to grab the popcorn.
GLA
AADi; Advenchem, Lilly Grant/Contract, Research funding.
C. Plummer,
Amgen; Servier Grant/Contract, Honoraria.
P. Loadman,
Avacta Grant/Contract, Paid consultant.
G. Lahu,
ThinkQ2 AG Employment.
Avacta Grant/Contract, Paid consultant.
H. S. Jones,
Avacta Grant/Contract, Paid consultant.
N. Kinnersley,
Avacta Grant/Contract, Paid consultant.
F. McLaughlin,
Avacta Employment.
C. Twelves,
MSD, Eisai, Daiichi-Sankyo, AstraZeneca, Pfizer, Lilly, Novartis and Gilead Grant/Contract, Travel, Advisory boards and research funding.
Abstract
Abstract is embargoed at this time.
CT188 / 16 - A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Add to My Itinerary
April 9, 2024, 9:00 AM - 12:30 PM Section 48
Presenter/Authors
U. Banerji1, N. Cook2, A. Anthoney3, R. Plummer4, W. D. Tap5, J. T. R. Evans6, L. D. Cranmer7, C. Plummer8, P. Loadman9, G. Lahu10, H. S. Jones9, N. Kinnersley11, F. McLaughlin12, C. Twelves8;
1The Institute of Cancer Research, Sutton, Sutton, United Kingdom, 2The Christie NHS Foundation Trust, Manchester, United Kingdom, 3The University of Leeds, Leeds, United Kingdom, 4Newcastle University, Newcastle, United Kingdom, 5Memorial Sloan Kettering Cancer Center, New York, NY, 6University of Glasgow, Glasgow, United Kingdom, 7University of Washington Fred Hutchinson Cancer Center, Seattle, WA, 8University of Leeds, Leeds, United Kingdom, 9University of Bradford, Bradford, United Kingdom, 10ThinkQ2 AG, Baar, Switzerland, 11Octa Consulting Group, Harpenden, United Kingdom, 12Avacta Therapeutics, London, United Kingdom
Disclosures
U. Banerji,
Phoenix Solutions; PharmEnable; Ellipses Pharma Grant/Contract, Advisory board.
AstraZeneca; Onyx; Chugai; BTG; Verastem Grant/Contract, Research funding.
N. Cook,
Roche; RedEx Grant/Contract, Advisory boards.
AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, Stemline Therapeutics, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck, Tar Grant/Contract, Research funding.
A. Anthoney, None.
R. Plummer,
Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa Benevolent AI and Sanofi Aventis Grant/Contract, Advisory board.
Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, and AstraZeneca Grant/Contract, IDMC honoraria.
AstraZeneca, Novartis, Bayer, MSD and BMS Grant/Contract, Travel, Educational talks with grant/travel.
W. D. Tap,
Atropos; Certis Stock.
AmMax; Amgen; BioAtla; Boehringer Ingelheim; Cogent; Daiichi Sankyo; Deciphera; InhibRx; Servier; Per Events; PVI Grant/Contract, Research Funding/Advisory board.
J. T. R. Evans,
Ascelia, Astra Zeneca, Bayer, Bicycle Therapeutics, Bristol-Myers Squibb, Celgene, Eisai, Karus Therapeutics, Medivir, MSD, Otsuka, Roche, and Seagen Grant/Contract, Honoraria.
Astra Zeneca, Ascelia, Bayer, Bristol Myers Squibb, Celgene, Eisai, Nucana, MSD, Roche, Medivir, and United Medical Grant/Contract, Speaker fees.
Bristol-Myers Squibb; Roche; MSD; Pierre-Fabre; Celgene; Bayer Travel.
Astra Zeneca, Basilea, Bayer, Celgene, MiNa Therapeutics, Roche, Pfizer, Sierra, Lilly, Eisai, GSK, Novartis, Bicycle Therapeutics, Johnson and Johnson, CytomX, Vertex, Plexxikon, Boehringer, Athinex Grant/Contract, Clinical trial grants to institution.
L. D. Cranmer,
Blueprint Medicines Grant/Contract, Advisory board.
AADi; Advenchem, Lilly Grant/Cont
🤡 voting
"Without additional funds in excess of £20m, the Company would not have been able to progress any of its pre-clinical pipeline, which we believe will drive significant future shareholder value well beyond AVA6000.
Stop being a greedy twat and get a BP partner on board ASAP most LTH’s would like some professional help maximising this platform.
Put a stop to your silly games…
Shocking one guy on twitter lost all his investment his wife and kid, he is in a dark place other PI’s pleading with him to not do anything stupid…
Then there is Smith & Gardiner laughing in the City.
Holy grail in Cancer treatment.
What about mental health ?
They both need to go,funding could of been sorted months ago.
It’s not just PI’s, Wetherby’s Bonnie & Clyde have had over, just two weeks earlier they
RNS’s this:
Award Scheme, ordinary shares of 10p each in the Company ("Ordinary Shares") up to a value of £3,000 per employee will be issued at the prevailing middle market price at the close of business on 14 February 2024 to all eligible employees. These shares awarded will form part of the employee's remuneration package.
Imagine getting a bonus for all your hard work then your boss reduces by 50% two weeks later.
Hang your heads in shame Smith & Gardiner do the right thing and resign.